Despite this notification, the company’s listing remains effective for the time being. Tivic Health has been granted a compliance period of 180 calendar days, until September 15, 2026, to regain compliance with the minimum bid price requirement. If the company's stock price closes at or above $1.00 per share for a minimum of 10 consecutive business days during this period, Nasdaq will notify the company that it has achieved compliance.
Should Tivic Health fail to regain compliance within the allotted time, Nasdaq may provide a second 180-day grace period, contingent upon the company meeting other continued listing requirements. The company has expressed its intention to actively monitor its stock price and explore options to resolve this deficiency. However, there is no guarantee that it will successfully regain compliance or avoid delisting.
This situation raises concerns regarding the company's operational execution and strategy outlook, as a prolonged period of low stock prices could hinder its ability to raise capital and invest in growth initiatives. Investors will be closely watching how Tivic Health navigates this challenge in the coming months, as the implications of a potential delisting could significantly impact shareholder value and market perception.
